trending Market Intelligence /marketintelligence/en/news-insights/trending/H6D6kh9ACumMXgo-KJ5_zg2 content esgSubNav
In This List

Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


Novartis drug prolongs time to patients' first sickle cell pain crisis in study

Novartis AG drug crizanlizumab delayed the time to first sickle cell pain crisis in patients versus placebo in key subgroups of adult patients with sickle cell disease in a phase 2 trial.

Acute sickle cell pain crises are a common painful complication of the disease and the main reason that patients seek medical care in hospitals. They are also known as vaso-occlusive crises.

The data will help support discussions with regulatory agencies, with filing expected in the U.S. by the end of 2018.